

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 **1-69.** (Cancel)


2 **70.** (Currently amended and withdrawn) A pharmaceutical composition

3 comprising a pharmaceutically acceptable excipient and a compound of any one of Claims **58**

4 **and 59 118 and 119.**

5 **71-117.** (Cancel)

6 **118.** (New) A compound having a formula



7 and their pharmaceutically acceptable salts, wherein

8 P² is selected from the group consisting of —C(O)—, —CH(OH)—, —C(O)O—,

9 —OC(O)—, —NHC(O)NH—, —OC(O)NH—, —NHC(O)O—, —C(O)NH—, —NHC(O)—,

10 and O(CH₂CH₂O)_q;

11 P³ is selected from the group consisting of C₂-C₆ alkynyl, C₁-C₆ haloalkyl, aryl,

12 heteroaryl, -NHS(O)₂R², —C(O)OR² and carboxylic acid analogs, wherein R² is a member

13 selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄

14 alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted


15 aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl;

16 the subscript q is 0 to 3;

17 L¹ is unsubstituted C₂-C₆ alkylene or substituted C₂-C₆ alkylene;

18 L² is unsubstituted C₂-C₁₂ alkylene or substituted C₂-C₁₂ alkylene.

19 **119.** (New) A compound having a formula (I):



21 and their pharmaceutically acceptable salts, wherein
22 R^1 is a member selected from the group consisting of aryl and heteroaryl;
23 P^1 is a primary pharmacophore selected from the group consisting of —
24 $NHC(O)NH-$, $-OC(O)NH-$, $-NHC(O)O-$, $-CH_2C(O)NH-$, $-C(O)NH-$ and —
25 $NHC(O)-$;
26 P^2 is a secondary pharmacophore selected from the group consisting of $-C(O)-$,
27 $-CH(OH)-$, $-O(CH_2CH_2O)_q-$, $-C(O)O-$, $-OC(O)-$, $-NHC(O)NH-$, $-OC(O)NH-$,
28 $-NHC(O)O-$, $-C(O)NH-$ and $-NHC(O)-$;
29 P^3 is a tertiary pharmacophore selected from the group consisting of C_2-C_6
30 alkynyl, C_1-C_6 haloalkyl, aryl, heteroaryl, $-C(O)NHR^1$, $-C(O)NHS(O)_2R^1$, $-NHS(O)_2R^2$,
31 $-C(O)OR^2$ and carboxylic acid analogs, wherein R^2 is a member selected from the group
32 consisting of hydrogen, unsubstituted C_1-C_4 alkyl, substituted C_1-C_4 alkyl, unsubstituted C_3-C_8
33 cycloalkyl, substituted C_3-C_8 cycloalkyl, unsubstituted aryl, substituted aryl, unsubstituted aryl
34 C_1-C_4 alkyl, and substituted aryl C_1-C_4 alkyl;
35 the subscripts n and m are each independently 0 or 1, and at least one of n or m is
36 1, and the subscript q is 0 to 3;
37 L^1 is a first linker selected from the group consisting of unsubstituted C_2-C_6
38 alkylene, substituted C_2-C_6 alkylene, unsubstituted C_3-C_6 cycloalkylene, substituted C_3-C_6
39 cycloalkylene, unsubstituted arylene, substituted arylene, unsubstituted heteroarylene, and
40 substituted heteroarylene; and
41 L^2 is a second linker selected from the group consisting of unsubstituted C_2-C_{12}
42 alkylene, substituted C_2-C_{12} alkylene, unsubstituted arylene, substituted arylene, and
43 combinations thereof.
44 **120.** (New) The compound according to any one of claims 118 and 119,
45 wherein P^3 is $-C(O)OR^2$ or a carboxylic acid analog, wherein R^2 is selected from the group

47 consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈
48 cycloalkyl, and substituted C₃-C₈ cycloalkyl.

49 **121.** (New) The compound according to any one of Claims 118 and 119,
50 wherein P³ is -C(O)OR² or a carboxylic acid analog, wherein R² is selected from the group
51 consisting of hydrogen, methyl, and ethyl.

52 **122.** (New) The compound of Claim 119, wherein R¹ is selected from the
53 group consisting of phenyl and naphthyl.

54 **123.** (New) The compound of Claim 119, wherein R¹ is phenyl.

55 **124.** (New) The compound Claim 119, wherein R¹ is phenyl, wherein the
56 phenyl is either unsubstituted or substituted with from one to three substituents selected from the
57 group consisting of halogen, lower alkyl, lower halo alkyl, lower alkoxy, C₃-C₅ cycloalkyl, and
58 cyano.

59 **125.** (New) The compound of Claim 119, wherein P¹ is selected from the
60 group consisting of -NHC(O)CH-, -OC(O)NH-, and -NHC(O)O-.

61 **126.** (New) The compound of Claim 119, wherein P¹ is -NHC(O)CH-.

62 **127.** (New) The compound of Claim 119, wherein L¹ is an alkylene of from 2
63 to 4 carbon atoms,

64 P² is not present; and

65 L² is an alkylene of from 2 to 8 carbon atoms.

66 **128.** (New) The compound of Claim 119, wherein P¹ is selected from the
67 group consisting of —NHC(O)NH—, -OC(O)NH— and —NHC(O)O—;

68 n is 0;





69 m is 1;

70 L¹ is selected from the group consisting of unsubstituted C₂-C₆ alkylene,
71 unsubstituted C₃-C₆cycloalkylene, substituted C₃-C₆cycloalkylene, unsubstituted arylene, and
72 substituted arylene;


73 L² is selected from the group consisting of unsubstituted C₂-C₆ alkylene and
74 substituted C₂-C₆ alkylene; and

75 P³ is selected from the group consisting of C₂-C₆ alkynyl, C₁-C₆ haloalkyl, aryl,
76 heteroaryl, —C(O)NHR², —C(O)NHS(O)₂R², —NHS(O)₂R², —C(O)OR², and carboxylic acid
77 analogs, wherein R² is a member selected from the group consisting of hydrogen, unsubstituted
78 C₁-C₄ alkyl, substituted C₁-C₄ alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl,
79 unsubstituted aryl, substituted aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄
80 alkyl.


81 **129.** (New) A compound having the formula selected from the group
82 consisting of:




87




88




89




90




91




92




93




94




95




96




97




98




99




100




101




102

















103




104




- 105  ,
- 106  ,
- 107  ,
- 108  ,
- 109  ,
- 110  ,




119




120




121




122




123




124




125




126




127




128




129




130




131




132




133












134




135







145




146




147




148




149




150




151




152







153




154




155




156



157



158



159

wherein Z is O or NH;

161

163

n1 is 1, 2, 3, 4, 6, 7, 9, 10, or 11;

163

n2 is 1, 2, 3, or 4;

164

n3 is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;


165

and their pharmaceutically acceptable salts.

166

130. (New) A compound having the formula:


167



168

131. (New) A compound having a formula

169



170

and their pharmaceutically acceptable salts, wherein

171

172 heteroaryl, -NHS(O)₂R², —C(O)OR² and carboxylic acid analogs, wherein R² is a member
173 selected from the group consisting of hydrogen, unsubstituted C₁-C₄ alkyl, substituted C₁-C₄
174 alkyl, unsubstituted C₃-C₈ cycloalkyl, substituted C₃-C₈ cycloalkyl, unsubstituted aryl, substituted
175 aryl, unsubstituted aryl C₁-C₄ alkyl, and substituted aryl C₁-C₄ alkyl;

176

the subscript m is 1;

177

L^1 is unsubstituted C₃-C₄ alkylene or substituted C₃-C₄ alkylene;

178

179

181

